Morepen Q1 FY27 revenue up 34%, PAT jumps 394% YoY; CDMO goes full scale

Revenue growth above 20%Profit growth above 25%EBITDA margin expansionResults View source PDF Explain this filing

MOREPENLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+20.5%Reaction day

₹57.40

prior close

₹68.18

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.4%+20.1% vs market

Pharmaceuticals peers, median of 165sector-0.0%+20.6% vs sector

On the reaction day the stock moved 20.1 pts more than Nifty Microcap 250 and 20.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.5

10m

+1.5

15m

+1.5

30m

+1.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+20.5+0.4+20.1-0.0+20.6

Next day

+33.6+1.7+31.9+0.0+33.6

+38.6+2.1+36.5+0.2+38.4

+39.4+2.1+37.3+0.4+39.0

+39.5+2.1+37.5+0.6+38.9

+33.8+1.9+31.9+0.8+33.0

+41.6+2.4+39.2+0.4+41.3

15d

+63.4+3.0+60.4+0.5+63.0

+97.9+3.7+94.2+1.0+96.9

+136.4+1.6+134.9+2.0+134.5

+82.8-2.7+85.5-2.5+85.4

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Morepen Labs posted its highest-ever quarterly revenue of Rs. 575.31 Cr in Q1 FY27, up 34% YoY. EBITDA surged 207% YoY to Rs. 87.72 Cr with margin improving to 15.25% from 6.65%. PAT jumped 394% YoY to Rs. 56.35 Cr. Exports grew 111% and API exports rose 42%. The Rs. 825 Cr CDMO mandate entered full scale commercialization with Rs. 58 Cr dispatches already done. Medical devices grew 19%. Four consecutive USFDA inspections had zero observations.

Likely market impact

Strong across-the-board growth with massive PAT jump signals improving profitability and successful CDMO transition, likely positive for stock sentiment.

By the numbersConsolidated · Q1 FY27 vs Q1 FY26

	Q1 FY27	Q1 FY26	Change
Revenue	₹570.1 Cr	₹425.2 Cr	+34.1%
Operating profit	₹69.34 Cr	₹11.11 Cr	+524.3%
Profit after tax	₹56.40 Cr	₹10.75 Cr	+424.7%
EBITDA margin	14.5%	5.7%	+8.8 pp

From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.